Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk AS

www.novonordisk.com

Latest From Novo Nordisk AS

Scottish HTA Finally OKs Roche’s Perjeta For Metastatic Breast Cancer

The Scottish health technology assessment body, the SMC, has recommended a number of products for funding under NHS Scotland: Roche’s breast cancer drug Perjeta, Pfizer’s Xeljanz for psoriatic arthritis, and two antidiabetics, MSD’s Steglatro (ertugliflozin) and Novo Nordisk’s Ozempic (semaglutide).

 

Health Technology Assessment United Kingdom

House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses

Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.

Pricing Debate Legislation

AZ Management Shake-Up Sees CMO Bohen Exit

Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.

Leadership Strategy

In A Record Year For US FDA Approvals, Pfizer Came Out On Top

FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders. 
Approvals Drug Review
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register